Elevar Therapeutics and Hengrui Pharma have resubmitted applications to the FDA seeking approval of rivoceranib plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results